Kajian Literatur: Efektivitas Antibiotik Golongan Beta-Laktam pada Pasien Lansia dengan Pneumonia Komunitas

Afelia Mettania Wijaya, Fauna Herawati, Rika Yulia

Abstrak


Antibiotik golongan beta-laktam memiliki efektivitas yang baik pada pasien dewasa. Lansia dan dewasa memiliki perbedaan baik fisik maupun psikis yang mengakibatkan efektivitas dan rekomendasi jenis antibiotik juga mengalami perbedaan. Penelitian ini bertujuan untuk memberikan informasi terkait efektivitas serta rekomendasi antibiotik golongan beta-laktam pada pasien lansia dengan Pneumonia Komunitas. Penelitian ini merupakan kajian literatur yang menggunakan artikel dengan beberapa desain studi. Kualitas jurnal dinilai dengan Critical Appraisal Skills Programme (CASP) checklist dan reputasi jurnal. Didapatkan 9 artikel memenuhi kriteria dan berkualitas baik. Berdasarkan hasil sintesis, antibiotik golongan beta-laktam yang sering digunakan untuk mengatasi pneumonia komunitas pada lansia adalah Ceftriaxone, ertapenem, ampicillin/sulbactam, biapenem, dan Imipenem/cilastatin. Efektivitas antibiotik beta-laktam pada lansia dengan pneumonia komunitas ditentukan oleh 3 kriteria, yaitu clinical efficacy, microbiological efficacy, dan treatment duration. Secara keseluruhan, antibiotik golongan beta-laktam yang dapat menjadi rekomendasi dan memiliki efektivitas terbaik dalam mengatasi pneumonia komunitas pada lansia adalah Cefepime. Kemudian ertapenem dan biapenem pada rekomendasi kedua, serta Meropenem pada rekomendasi ketiga. Penelitian ini masih memiliki kelemahan karena informasi yang terbatas mengenai topik, beberapa artikel dengan resiko bias sedang, dan beberapa artikel hasil pencarian yang menggunakan artikel diluar bahasa inggris.


Kata Kunci


pneumonia komunitas; efektivitas; antibiotik; beta-laktam; lansia

Teks Lengkap:

PDF

Referensi


. Astiti PMA, Mukaddas A, Illah SA. Identifikasi Drug Related Problems (DRPs) Pada Pasien Pediatri Pneumonia Komunitas di Instalasi Rawat Inap RSD Madani Provinsi Sulawesi Tengah: Identification of Drug Related Problems In Pediatric Patients With Community Acquired Pneumonia at Madani Hospi. J Farm Galen (Galenika J Pharmacy). 2017;3(1):57–63. https://doi.org/10.22487/j24428744.2017.v3.i1.8140

. Efni Y, Machmud R, Pertiwi D. Faktor Risiko yang Berhubungan dengan Kejadian Pneumonia pada Balita di Kelurahan Air Tawar Barat Padang. J Kesehat Andalas. 2016;5(2):365–70. https://doi.org/10.25077/jka.v5i2.523

. Han X, Zhou F, Li H, Xing X, Chen L, Wang Y, et al. Effects of age, comorbidity and adherence to current antimicrobial guidelines on mortality in hospitalized elderly patients with community-acquired pneumonia. BMC Infect Dis. 2018;18(1):1–11. https://doi.org/10.1186/s12879-018-3098-5

. Rivero-Calle I, Cebey-López M, Pardo-Seco J, Yuste J, Redondo E, Vargas DA, et al. Lifestyle and comorbid conditions as risk factors for community-acquired pneumonia in outpatient adults (NEUMO-ES-RISK project). BMJ Open Respir Res. 2019;6(1):1–9. https://doi.org/10.1136/bmjresp-2018-000359

. Aston SJ. Pneumonia in the developing world: Characteristic features and approach to management. Respirology. 2017;22(7):1276–87. https://doi.org/10.1111/resp.13112

. Petrosillo N, Cataldo MA, Pea F. Treatment options for community-acquired pneumonia in the elderly people. Expert Rev Anti Infect Ther. 2015;13(4):473–85. https://doi.org/10.1586/14787210.2015.1021783

. Viasus D, Núñez-Ramos JA, Viloria SA, Carratalà J. Pharmacotherapy for community-acquired pneumonia in the elderly. Expert Opin Pharmacother. 2017;18(10):957–64. https://doi.org/10.1080/14656566.2017.1340940

. Kementerian Kesehatan RI. Peraturan Menteri Kesehatan Republik Indonesia. Peratur Menteri Kesehat No 2406 TAHUN 2011 tentang Pedoman Umum Pengguna Antibiot. 2011;73.

. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. Am J Respir Crit Care Med. 2019;200(7):E45–67. https://doi.org/10.1164/rccm.201908-1581ST

. Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone PM, Kolesar JM, DiPiro JT, et al. Pharmacotherapy principles & practice. 2016.

. Lew KY, Ng TM, Tan M, Tan SH, Lew EL, Ling LM, et al. Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting. J Antimicrob Chemother. 2014;70(4):1219–25. https://doi.org/10.1093/jac/dku479

. Karino F, Deguchi N, Kanda H, Ohe M, Kondo K, Tada M, et al. Evaluation of the efficacy and safety of biapenem against pneumonia in the elderly and a study on its pharmacokinetics. J Infect Chemother. 2013;19(1):98–102. https://doi.org/10.1007/s10156-012-0463-y

. Namkoong H, Kameyama Y, Yasuda H, Nakayama S, Kaneko H, Kawashima C, et al. The efficacy, safety, and pharmacokinetics of biapenem administered thrice daily for the treatment of pneumonia in the elderly. J Infect Chemother. 2014;20(6):356–60. https://doi.org/10.1016/j.jiac.2013.12.010

. Chapman TM, Perry CM. Cefepime: A review of its use in the management of hospitalized patients with pneumonia. Am J Respir Med. 2003;2(1):75–107. https://doi.org/10.1007/BF03256641

. Lodise TP, Kwa A, Cosier L, Gupta R, Smith RP. Comparison of β-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized veterans affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother. 2007;51(11):3977–82. https://doi.org/10.1128/AAC.00006-07

. Murcia JM, González-Comeche J, Marín A, Barberán J, Granizo JJ, Aguilar L, et al. Clinical response to ertapenem in severe community-acquired pneumonia: A retrospective series in an elderly population. Clin Microbiol Infect. 2009;15(11):1046–50. https://doi.org/10.1111/j.1469-0691.2009.02843.x

. Yanagihara K, Fukuda Y, Seki M, Izumikawa K, Higashiyama Y, Miyazaki Y, et al. Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia. Intern Med. 2006;45(17):995–9. https://doi.org/10.2169/internalmedicine.45.1717

. Raschilas F, Tigoulet F, Durant R, Blain H, Jeandel C. Ertapanem therapy for community-acquired pneumonia in the elderly. J Am Geriatr Soc. 2004;52(10):1526–32. https://doi.org/10.1111/j.1532-5415.2004.52479_11_1.x

. Rossio R, Franchi C, Ardoino I, Djade CD, Tettamanti M, Pasina L, et al. Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. Eur J Intern Med. 2015;26(5):330–7. https://doi.org/10.1016/j.ejim.2015.04.002

. Okimoto N, Kurihara T, Honda N, Asaoka N, Fujita K, Ohba H, et al. Clinical effect of ampicillin with β-lactamase inhibitor (sulbactam/ampicillin) on community-acquired pneumonia in the elderly. J Infect Chemother. 2003;9(2):183–6. https://doi.org/10.1007/s10156-003-0233-Y

. Grossman RF, Campbell DA, Landis SJ, Garber GE, Murray G, Stiver HG, et al. Treatment of community-acquired pneumonia in the elderly: The role of cefepime, a fourth-generation cephalosporin. J Antimicrob Chemother. 1999;43(4):549–54. https://doi.org/10.1093/jac/43.4.549




DOI: https://doi.org/10.25077/jsfk.8.2.80-92.2021

Article Metrics

Abstract view : 786 times
PDF view/download : 374 times



Jurnal Sains Farmasi & Klinis (J Sains Farm Klin) | p-ISSN: 2407-7062 | e-ISSN: 2442-5435

Diterbitkan oleh Fakultas Farmasi Universitas Andalas bekerjasama dengan Ikatan Apoteker Indonesia - Daerah Sumatera Barat 

      

 JSFK is licensed under Creative Commons Attribution-ShareAlike 4.0 International License.